Literature DB >> 15305014

Mammalian phospholipase A2: phospholipase A2 receptor.

Kohji Hanasaki1.   

Abstract

The phospholipase A2 receptor (PLA2R) is a type I transmembrane glycoprotein related to the C-type animal lectin family such as the mannose receptor. PLA2R regulates a variety of biological responses elicited by secretory phospholipase A2s (sPLA2s). Group IB sPLA2 acts as an endogenous ligand to induce cell proliferation and lipid mediator production. Analysis of PLA2R-deficient mice suggested a potential role of the sPLA2-IB/PLA2R pathway in the production of proinflammatory cytokines during endotoxic shock. PLA2R is also involved in the clearance of sPLA2s, especially group X sPLA2, to protect their exaggerated reactions by potent enzymatic activities. In circulation, the soluble form of PLA2R is constitutively present as an endogenous inhibitor for mammalian sPLA2s.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305014     DOI: 10.1248/bpb.27.1165

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  16 in total

Review 1.  SASP reflects senescence.

Authors:  Andrew R J Young; Masashi Narita
Journal:  EMBO Rep       Date:  2009-02-13       Impact factor: 8.807

Review 2.  Genetics of kidney failure and the evolving story of APOL1.

Authors:  David J Friedman; Martin R Pollak
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

3.  Anti-phospholipase A2 receptor antibody in membranous nephropathy.

Authors:  Weisong Qin; Laurence H Beck; Caihong Zeng; Zhaohong Chen; Shijun Li; Ke Zuo; David J Salant; Zhihong Liu
Journal:  J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 10.121

4.  A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism.

Authors:  Katherine J Bryant; Matthew J Bidgood; Pei-Wen Lei; Megan Taberner; Caroline Salom; Vinod Kumar; Lawrence Lee; W Bret Church; Brett Courtenay; Brian P Smart; Michael H Gelb; Michael A Cahill; Garry G Graham; H Patrick McNeil; Kieran F Scott
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

Review 5.  Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.

Authors:  Farnaz Fouladi; Kristine J Steffen; Sanku Mallik
Journal:  Bioconjug Chem       Date:  2017-03-08       Impact factor: 4.774

6.  Nonbactericidal secreted phospholipase A2s are potential anti-inflammatory factors in the mammary gland.

Authors:  Eyal Seroussi; Shelly Klompus; Maayan Silanikove; Oleg Krifucks; Fira Shapiro; Arieh Gertler; Gabriel Leitner
Journal:  Immunogenetics       Date:  2013-10-03       Impact factor: 2.846

7.  Analysis of several PLA2 mRNA in human meningiomas.

Authors:  Yves Denizot; Rafael De Armas; Karine Durand; Sandrine Robert; Jean-Jacques Moreau; François Caire; Nicolas Weinbreck; François Labrousse
Journal:  Mediators Inflamm       Date:  2010-03-21       Impact factor: 4.711

8.  An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.

Authors:  Astrid Behnert; Marvin J Fritzler; Beina Teng; Meifeng Zhang; Frank Bollig; Hermann Haller; Andrej Skoberne; Michael Mahler; Mario Schiffer
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

9.  Modulation of the pharmacological effects of enzymatically-active PLA2 by BTL-2, an isolectin isolated from the Bryothamnion triquetrum red alga.

Authors:  Simone Cb Oliveira; Fabiana V Fonseca; Edson Antunes; Enilton A Camargo; Rafael P Morganti; Ricardo Aparício; Daniela O Toyama; Luís Os Beriam; Eudismar V Nunes; Benildo S Cavada; Celso S Nagano; Alexandre H Sampaio; Kyria S Nascimento; Marcos H Toyama
Journal:  BMC Biochem       Date:  2008-06-06       Impact factor: 4.059

10.  Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.

Authors:  Mario Menschikowski; Albert Hagelgans; Brit Nacke; Carsten Jandeck; Olga Sukocheva; Gabriele Siegert
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.